STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive: It was found that pimozide can inhibit the critical tyrosine residue phosphorylation, which is needed to activate STAT5, when administered to established CML cell lines, KU812 and KU562, but has non-significant effects in the inhibition of Bcr-Abl or other SFKs [105].